250 related articles for article (PubMed ID: 33729700)
1. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer.
Liu X; Li Z; Wang Y
Adv Biol (Weinh); 2021 Mar; 5(3):e1900236. PubMed ID: 33729700
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment for advanced pancreatic cancer.
Leowattana W; Leowattana P; Leowattana T
World J Gastrointest Oncol; 2023 Oct; 15(10):1691-1705. PubMed ID: 37969416
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer.
Cao D; Song Q; Li J; Jiang Y; Wang Z; Lu S
Expert Rev Mol Med; 2021 Dec; 23():e21. PubMed ID: 34906271
[TBL] [Abstract][Full Text] [Related]
4. Progress and prospects for use of cellular immunotherapy in pancreatic cancer.
Tian J; Bai T; Zhang Z; Zhai X; Wang K; Gao X; Yan B
J Cancer Res Ther; 2022 Dec; 18(7):1867-1875. PubMed ID: 36647944
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of pancreatic cancer.
Sunami Y; Kleeff J
Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
[TBL] [Abstract][Full Text] [Related]
6. What is recent in pancreatic cancer immunotherapy?
Niccolai E; Prisco D; D'Elios MM; Amedei A
Biomed Res Int; 2013; 2013():492372. PubMed ID: 23509731
[TBL] [Abstract][Full Text] [Related]
7. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for pancreatic cancer: A 2020 update.
Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
[TBL] [Abstract][Full Text] [Related]
9. The role of adjuvant therapy for pancreatic cancer.
Magee CJ; Ghaneh P; Hartley M; Sutton R; Neoptolemos JP
Expert Opin Investig Drugs; 2002 Jan; 11(1):87-107. PubMed ID: 11772324
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
11. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
Cancer Lett; 2017 Mar; 388():139-148. PubMed ID: 27916607
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic developments in pancreatic cancer: current and future perspectives.
Neoptolemos JP; Kleeff J; Michl P; Costello E; Greenhalf W; Palmer DH
Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):333-348. PubMed ID: 29717230
[TBL] [Abstract][Full Text] [Related]
13. Current Status of Immunotherapy Treatments for Pancreatic Cancer.
Jimenez-Luna C; Prados J; Ortiz R; Melguizo C; Torres C; Caba O
J Clin Gastroenterol; 2016; 50(10):836-848. PubMed ID: 27505403
[TBL] [Abstract][Full Text] [Related]
14. The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology.
Reccia I; Kumar J; Habib N; Sodergren M
Med Oncol; 2018 Oct; 35(12):151. PubMed ID: 30284649
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer.
Chadha AS; Khoo A; Aliru ML; Arora HK; Gunther JR; Krishnan S
Semin Radiat Oncol; 2016 Oct; 26(4):320-37. PubMed ID: 27619253
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
Ercan G; Karlitepe A; Ozpolat B
Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
[TBL] [Abstract][Full Text] [Related]
17. Current immunotherapeutic approaches in pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Tsukinaga S; Mitobe J; Odahara S; Yukawa T; Matsudaira H; Nagatsuma K; Uchiyama K; Satoh K; Ito M; Komita H; Arakawa H; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2011; 2011():267539. PubMed ID: 21922022
[TBL] [Abstract][Full Text] [Related]
18. Strategies to relieve immunosuppression in pancreatic cancer.
Schnurr M; Duewell P; Bauer C; Rothenfusser S; Lauber K; Endres S; Kobold S
Immunotherapy; 2015; 7(4):363-76. PubMed ID: 25917628
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy and pancreatic cancer.
Clary BM; Lyerly HK
Surg Oncol Clin N Am; 1998 Jan; 7(1):217-49. PubMed ID: 9443997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
